Blog
Making clinical development more investable with “financially adaptive trials”
Clinical trials are a terrible investment. But fear not – in our NRDD article, we show a path forward.
Where's the commercial innovation in pharma?
Pharma commercial teams are doing business like it's 2004 ... or maybe even 1994. It's time for a reboot.
Should pharma R&D and commercial "just be friends"?
GlaxoSmithKline is giving up its commercial presence in oncology, but keeping cancer R&D. This could be a huge deal, and a harbinger of things to come.
From bedside to bench and back again: Review of “Cured” by Nathalia Holt
In HIV and many other areas of biopharma, there are no shortcuts - sometimes science progresses a single patient at a time.
Baby biotech grows up: Review of "The Antidote" by Barry Werth
How do you build a drug company? Barry Werth continues the story of Vertex's birth and teenage years that he started with "Billion Dollar Molecule".
"Saving the winners" to improve pharma R&D
Adaptive trials could be a way to improve the pharma industry's dismal R&D success rates.
The future of pharma sales reps
Can you think of a good reason to have a Pharma sales force? Neither can I.
Academic medical centers and transparency of trial results
There's plenty of work to do to promote clinical data transparency. AMCs need to do their part.
Cancer R&D's tenuous value chain
To succeed in oncology drug development, Pharma execs need new approaches to clinical trials, diagnostics and pricing.
In defense of pharma forecasting
The problem isn't with Pharma forecasts – it's with how they're communicated and used in decision-making.